期刊
ANTIVIRAL RESEARCH
卷 75, 期 3, 页码 188-197出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2007.03.004
关键词
HIV-1; microbicide; synergy; antiretroviral; polyanion
资金
- Medical Research Council [G0400453] Funding Source: Medline
- Wellcome Trust [GR065513MA] Funding Source: Medline
- Medical Research Council [G0400453] Funding Source: researchfish
- MRC [G0400453] Funding Source: UKRI
Several polyanionic compounds with potential for use as topically applied microbicides to prevent HIV- I sexual transmission, such as PRO 2000, are currently in phase III clinical efficacy trials. Microbicidal formulations may well comprise combinations of inhibitors to increase potency, reduce dose and minimize problems of HIV- I resistance. We have therefore evaluated in vitro, the anti-HIV- I activity of two leading polyanionic microbicides combined with other antiretroviral agents with microbicidal potential. Dextran sulfate (DS) and PRO 2000 were combined with the neutralizing antibody IgG1 b 12, the peptide-based fusion inhibitor T20, the CCR5 antagonist TAK779 and the cyanobacterial protein cyanovirin-N. Anti-HIV-1 activity was assessed in a single cycle replication assay using pseudoviruses carrying a luciferase reporter gene and the envelope glycoproteins from HIV- I isolates JR-FL (R5) and HxB2 (X4), against both immortalized and primary CD4+ cell targets. The data were analyzed for synergy using Calcusyn(TM) software. Results indicate that PRO 2000 and DS can act synergistically with most inhibitors tested, although the degree of synergy depends on inhibitor concentration and combination. These data provide a rational basis for testing of microbicide combinations in vivo. (C) 2007 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据